更新于：2024-11-01

Urinary Bladder, Overactive

膀胱过度活动症

更新于：2024-11-01

基本信息

别名

Bladder instability、Bladder, Overactive、Detrusor Function, Overactive

+ [43]

简介

Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.

关联

138

项与膀胱过度活动症相关的药物

Gefapixant Citrate

靶点

P2X3 receptor

作用机制

P2X3 receptor拮抗剂

在研机构

Merck Sharp & Dohme BV [+1]

原研机构

F. Hoffmann-La Roche Ltd.

在研适应症

不明原因的慢性咳嗽 [+1]

非在研适应症

急性咳嗽 [+13]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2022-01-20

Vibegron

维贝格龙

靶点

β3-adrenergic receptor

作用机制

β3-adrenergic receptor激动剂

在研机构

Urovant Sciences Ltd. [+8]

原研机构

Merck & Co., Inc.

在研适应症

膀胱过度活动症综合征 [+5]

非在研适应症

内分泌系统疾病 [+3]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2018-09-21

Desfesoterodine Succinate

靶点

mAChRs

作用机制

mAChRs拮抗剂

在研机构

Ratiopharm GmbH

原研机构

Ratiopharm GmbH

在研适应症

膀胱过度活动症

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

德国

首次获批日期2017-07-04

1,218

项与膀胱过度活动症相关的临床试验

NCT06529198 / Not yet recruitingN/A

The NEUROGYN-GNS Pivotal Clinical Study to Assess the Safety and Efficacy of the Neurogyn Genital Neuromodulation System, a Genital Nerves Neuromodulation Device Used to Treat Idiopathic Overactive Bladder (iOAB).

The NeuroGyn study is designed to evaluate the safety and effectiveness to the NeuroGyn Genital Neuromodulation System as an aid in the treatment of the symptoms of idiopathic overactive bladder in patients who have failed or could not tolerate more conservative treatments.

开始日期2025-08-01

申办/合作机构-

NCT05910983 / Not yet recruitingN/AIIT

Prostate Enucleation With Intravesical Botox Injections in Treating Benign Prostatic Hyperplasia and Bladder Overactivity : A Randomized Controlled Trial

The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during Bipolar prostate enucleation surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB).

开始日期2025-01-01

申办/合作机构

Menoufia University

NCT05903105 / Not yet recruitingN/AIIT

The Preference of a Culturally and Linguistic Diverse (CALD) Population for Second Line OAB Therapy: a Discrete Choice Experiment

An overactive bladder (OAB) is a condition characterized by frequent en nightly voiding, small bladder capacity and the occurrence of sudden urge to void, with or without urinary incontinence. The prevalence of OAB with bothersome complaints is around 11% in women and 9% in men with an increasing incidence with age. OAB is not an illness or disease but nevertheless had a significant impact on both the individual as society. First-line treatment for OAB consists out of behavioral and physiotherapy. Anticholinergic medication can be associated to improve bothersome symptoms, but has the downside of causing unwanted side effects. If the formentioned treatment is not sufficient, second line treatment can be discussed. Depending on the patient's characteristics and the physician's preference intravesical injections of Botox or the implantation of a sacral neuromodulator (SNM) can be considered.
Both options are equal and effective, but many individual differences exist in preference. Regarding outcome, some factors have been described to prefer one therapy above the other, for example in case of concomitant fecal incontinence, frequent urinary tract infections,... The personal preference of doctors and patients has been investigated, but currently no study has focused on therapy preference in a culturally and linguistic divers (CALD) population. The latter broadly describes a population with ethnical, cultural, religious and/or language characteristics and is a general accepted measure of diversity.
In the current study, the investigators aim to describe the different (dis)advantages of both second line treatments for OAB in a discrete choice experiment. The study population will consist of a diverse group of patients with OAB from different hospitals. The goal is to investigate if CALD patients make a different choice in treatment and what factors contribute to that decision in order to provide more tailored information regarding the treatment options in the future. Taking a patient's context into account in the shared decision making between a patient and physician increases therapy compliance and satisfaction of the chosen treatment.
The total questionnaire will consist out of general demographic info, the EQ-5D, the International Consultation on Incontinence Questionnaire (ICIQ)-OAB and the discrete choice questionnaire in which patients make a choice between two fictional treatment options consisting of a combination of different therapy characteristics. The questionnaire will be translated into different languages in order to lower the threshold for participation.

开始日期2025-01-01

申办/合作机构

Ghent University Hospital

[+3]

100 项与膀胱过度活动症相关的临床结果

登录后查看更多信息

100 项与膀胱过度活动症相关的转化医学

登录后查看更多信息

0 项与膀胱过度活动症相关的专利（医药）

登录后查看更多信息

9,589

项与膀胱过度活动症相关的文献（医药）

2024-11-01·Current Opinion in Urology

Risk of dementia associated with the use of anticholinergic medications: a review of recent literature

Article

作者: Ziadeh, Hachem ; Sheyn, David ; Hijaz, Adonis ; Rhodes, Stephen

Purpose of reviewWhile there is an established association between the use of anticholinergic medications and its effects on cognition, the extent of this impact remains unclear. We outline recent studies addressing this topic.Recent findingsWe describe a series of recent articles discussing the risk of dementia associated with anticholinergic medication use in general, with further focus on the risk of overactive bladder (OAB) anticholinergic use, detailing short & long-term use effects, risk variation based on age and gender, and reporting alternative treatment options.SummaryAnticholinergic medication use bears an increased risk of dementia development, and accelerated cognitive decline in individuals with preexisting dementia, with the risk being related to the medications dosages, length of exposure, and pharmacological profile. β3-adrenoceptor agonists have proven to be a potent alternative for OAB anticholinergics, owing to its safe profile in regards of no clear effects on cognitive function, and having similar efficacy in OAB treatment.

2024-11-01·European Urology Open Science

Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms

Article

作者: Lee, Yung ; Cárdenas, Jovita L. ; Yoshimura, Koji ; Eryuzlu, Leyla ; Pryalukhin, Alexey ; Agarwal, Arnav ; te Brummelstroete, Gerhard H. ; Loohuis, Anne ; Witte, Lambertus P.W. ; Griebling, Tomas L. ; Vernooij, Robin W.M. ; Mynttinen, Henri ; Laakkonen, Sanna M. ; Bhatnagar, Neera ; Lopes, Luciane C. ; Izhar, Zain ; Brignardello-Petersen, Romina ; Salehi-Pourmehr, Hanieh ; Guyatt, Gordon H. ; Gutschon, Rachel E. ; Hallamies, Sanna K. ; Puerto Nino, Angie K. ; Bolsunovskyi, Kostiantyn ; van der Worp, Henk ; Violette, Philippe D. ; Aoki, Yoshitaka ; Siddiqui, Fahad J. ; Przydacz, Mikolaj ; Heikkilä, Katriina ; Tikkinen, Kari A.O. ; Mendieta, Alexander ; Bauer, Scott R. ; Gaudel, Pramila ; Elterman, Dean ; Tähtinen, Riikka ; Blanker, Marco H. ; Khurshid, Saqib ; Cartwright, Rufus ; Kilpeläinen, Tuomas P.

Multiple randomized controlled trials (RCTs) have examined first-line pharmacological agents such as anticholinergics and β3 agonists for the management of overactive bladder symptoms (OAB). Although earlier systematic reviews and (network) meta-analyses aimed to summarize the evidence, a substantial number of trials were not included, so a comprehensive and methodologically rigorous evaluation of the comparative effectiveness of all first-line pharmacological treatments is lacking. We aim to conduct a series of systematic reviews and network meta-analyses (NMAs) for a comprehensive assessment of the effectiveness and safety of first-line pharmacological treatments for OAB. Eligible studies will include RCTs comparing anticholinergics and β3 agonists to one another or to placebo in adults with OAB or detrusor overactivity. Pairs of reviewers with methodological training will independently evaluate candidate studies to determine eligibility and extract relevant data. We will incorporate patient-important outcomes, including urinary urgency episodes, urgency incontinence episodes, any type of incontinence episodes, urinary frequency, nocturia, and adverse events. We will conduct the NMAs using a frequentist framework and a graph theory model for each outcome. Analysis will follow rigorous methodologies, including handling of missing data and assessment of the risk of bias. We will conduct sensitivity and subgroup analyses and will apply the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to rate evidence certainty. Our approach aims to address the knowledge gap in the treatment of OAB by synthesizing evidence from RCTs worldwide. We will employ robust statistical methods, including frequentist NMA, to general clinically relevant and patient-important insights. Sensitivity and subgroup analyses will enhance the robustness and generalizability of our findings. Our reviews strive to inform evidence-based decisions in the management of OAB, to ultimate improve patient outcomes. Our study results may guide health policy decisions, such as reimbursement policies, and future studies in functional urology. The protocol for the review series is registered on PROSPERO as CRD42023266915.

2024-11-01·Neurourology and Urodynamics

Analysis of Variable Frequency Stimulation Sacral Neuromodulation for Different Genders: A Chinese Multicentric Prospective Clinical Study

Article

作者: Wang, Qingwei ; Niu, Yuanjie ; Song, Wei ; Wang, Jiawen ; Liu, Xiaodong ; Wei, Zhongqing ; Zhang, Yaoguang ; Wang, Jipeng ; Meng, Lingfeng ; Li, Yan ; Zhang, Zhipeng ; Shi, Benkang

ABSTRACTAimSacral neuromodulation (SNM) is widely recognized as the essential treatment modality for patients suffering from various lower urinary tract disorders, particularly overactive bladder (OAB). This prospective study recruited patients who underwent variable frequency SNM treatment at six Chinese medical centers, aiming to evaluate the gender‐specific effects of this intervention and provide precise guidance on its application for clinical management.MethodsThis prospective study was managed by Beijing Hospital, and six Chinese medical centers participated in this prospective research. Inclusion and exclusion criteria were established to screen patients based on the indication for SNM. During the research, all patients were required to record 72‐h voiding diaries, urgency scores, and visual analogue scale (VAS) scores to reflect their disease symptoms. Additionally, subjective questionnaire surveys such as OAB symptom score (OABSS) and quality‐of‐life (Qol) score were recorded to reflect the patients' quality of life and treatment satisfaction.ResultsIn this study, 52 patients (male patients: 25; female patients: 27) with OAB symptoms agreed to undergo variable frequency stimulation SNM therapy and finally convert to Stage II. Regarding the baseline outcomes, no significant differences were observed between the male and female groups. In terms of postoperative indicators, male patients showed a greater improvement in Qol scores compared to their female counterparts (20.06 ± 13.12 vs. 40.83 ± 26.06, p = 0.005). The results from VAS scores indicated that pain remission was more pronounced in male patients than in female patients (0.31 ± 0.87 vs. 1.67 ± 2.16, p = 0.02). Importantly, there was a statistically significant disparity in urinary urgency between males and females (male patients: 1.19 ± 1.56; female patients: 2.17 ± 1.52, p = 0.04).ConclusionsIn our study, we found that variable frequency SNM treatment yielded sex‐specific differences in therapeutic effects, with male patients having a better outcome in some metrics. This suggests that a patient's sex may influence when variable frequency SNM is used, and in the patient's follow‐up.Trial RegistrationClinicalTrials.gov identifier: ChiCTR2000036677.

236

项与膀胱过度活动症相关的新闻（医药）

2024-10-28

·PRNewswire

Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment

Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive Treatment BROOKLYN, N.Y., Oct. 28, 2024 /PRNewswire/ -- Vensica Medical ("Vensica"), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its revolutionary treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin®) delivered through a proprietary, needle-free device. Continue Reading (from l-r) Avner Geva, Vensica Therapeutics CEO & Co Founder; Avi Eftel, Vensica Therapeutics CTO & Co Founder The investment round was led by Israel Biotech Fund (IBF), alongside key strategic partners, Merz, a global player in neurotoxins, and Laborie, a prominent urology medical device company. This funding will enable Vensica to continue its mission of providing a minimally invasive, simple, and effective solution for people with overactive bladder ("OAB"). Vensica's unique technology leverages a needle-free drug delivery system, that administers Xeomin® directly to the bladder wall. This approach is expected to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica's needle-free drug delivery system aims to be a urology treatment platform for the treatment of additional bladder indications. "We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment," remarked Avner Geva, CEO of Vensica. "This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it." As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic application in several urologic indications and will benefit from Merz's clinical development support. This collaboration marks a significant step forward in the company's goal of delivering next-generation urology treatments. For more information on Vensica and its upcoming clinical trials, visit . About Vensica Medical Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. The company's leading product is a needle-free delivery system for Xeomin® (botulinum toxin A) aimed at treating overactive bladder in a minimally invasive manner. Vensica was established in the incubator program of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority. Contact: Avner Geva, Chief Executive Officer [email protected] Photo: SOURCE Vensica Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期

2024-10-17

·CPHI制药在线

浅谈子宫内膜异位症进展，和其瑞医药的HMI-115被纳入突破性治疗品种

关注并星标CPHI制药在线 10月15日，CDE官网显示，和其瑞医药（南京）有限公司1类新药「HMI-115」拟被纳入突破性治疗品种，用于治疗子宫内膜异位症相关的中重度疼痛。子宫内膜异位症是一种以内膜细胞种植在子宫内膜以外位置为特征的一种雌激素依赖的常见妇科疾病，通常表现为慢性炎症反应，常见症状包括下腹及盆腔痛、痛经、性交痛及不孕。子宫内膜异位症常见于育龄妇女，全球发病率在育龄妇女中约为10%。目前，子宫内膜异位症的病因尚不清楚，也无法治愈，常见治疗方式是止痛和治疗不孕症。 HMI-115是一款靶向泌乳素受体（PRLR）的单克隆抗体，被开发用于治疗子宫内膜异位症和雄激素性秃发，已在动物模型包括非人灵长类(NHP)模型和人体安全性方面展现出优异的特质。该药最初由拜耳作为治疗子宫内膜异位药物开发。2019年4月，和其瑞医药与拜耳签署一项全球独家许可协议，获得HMI-115在全球开展多个适应症的开发和产业化授权。 2014年1月，和其瑞医药宣布HMI-115治疗雄激素性脱发的临床1b期研究取得积极结果。该研究共入组16名雄激素性脱发（12名男性+4名女性）患者，HMI-115治疗24周时，12名男性患者的平均目标区域非毳毛数量与基线相比，每平方厘米增加了14根。同时，HMI-115展现出良好的安全性和耐受性。此次HMI-115被CDE纳入治疗子宫内膜异位症相关的中重度疼痛的突破性治疗品种，将加速HMI-115该适应症在国内的开发进程。国内在研子宫内膜异位症新药进展除了HMI-115，国内还有多款新药被开发用于治疗子宫内膜异位症相关的中重度疼痛，详见下表。在研药物靶点相对集中，主要为GnRH。研发进度上，大多处于1期临床。 Linzagolix进展较快，在国内处于3期临床。该药是Kissei Pharmaceutical开发的一款新型、口服、非肽类促性腺激素释放激素（GnRH）受体拮抗剂，2022年6月在欧盟及英国被批准用于治疗育龄妇女子宫肌瘤中度至重度症状。Linzagolix是第一个获批在非激素给药选择下的口服GnRH拮抗剂，2021年9月，葆正医药与Kissei Pharmaceutical达成授权协议，获得Linzagolix在中国的开发和商业化权利。2022年10月，Linzagolix在国内获批临床，用于治疗子宫内膜异位症相关的疼痛。 HS-10518等多款药物处于1期临床。其中HS-10518是一款靶向于GnRH的1类新药，拟用于治疗子宫内膜异位症相关中重度疼痛、子宫肌瘤相关月经过多等疾病。目前，HS-10518正处于Ⅰ期临床阶段，将在中国健康绝经前成年女性受试者中开展研究。 CMS-D002是康哲药业自主研发的一款小分子GnRH受体拮抗剂，通过与内源性GnRH竞争性结合垂体上的GnRH受体，在中枢神经水平阻断垂体性腺轴，减少内源性FSH和LH的释放，从而抑制下游雌激素、黄体酮和睾酮的分泌，缓解性激素相关疾病的进展。临床前研究表明：CMS-D002具有优异的有效性和安全性，有望开发用于治疗子宫内膜异位症、子宫肌瘤、前列腺癌等疾病。2024年2月，CMS-D002在国内获批临床。 G201-Na是以岭药业的一款小分子GnRH受体拮抗剂，临床前研究显示其药效确切、安全性良好。 BAY 1817080是一款在研P2X3拮抗剂，被开发用于治疗子宫内膜异位症、慢性咳嗽、膀胱过动症等多种疾病。P2X3受体是嘌呤类受体家族中的一员，是非选择性的配体门控离子通道，研究发现其表达在上皮细胞和感觉神经元上，而且P2X3受体的高表达和激活可以导致慢性疼痛模型动物的痛觉敏化。2021年1月，BAY 1817080在国内获批临床，用于治疗子宫内膜异位症。 SHR7280是恒瑞医药研发的一种新型口服小分子GnRH受体拮抗剂。药效学分析显示，SHR7280能够有效抑制雌二醇和黄体生成素浓度，并以剂量依赖的方式防止孕激素升高。已公布的SHR7280在子宫内膜异位症的绝经前期女性患者中开展的1/2期临床研究结果显示：该药在绝经前期女性患者中表现出良好的耐受性和药代动力学特性。此外，GnRH受体拮抗剂瑞卢戈利和艾拉戈克钠也在国内被开发用于治疗子宫内膜异位症相关的疼痛。其中瑞卢戈利是武田开发的一种可口服、非肽类小分子促性腺激素释放激素（GnRH）受体拮抗剂，2019年1月在日本获批，用于改善子宫肌瘤引起的下列症状：月经过多、下腹痛、腰痛、贫血和改善子宫内膜异位症引起的疼痛。目前，国内民生药业、齐鲁制药在开展瑞卢戈利改善子宫肌瘤引起的一些症状，如月经过多、下腹痛、腰痛、贫血等，以及改善子宫内膜异位症引起的疼痛的人体生物等效性试验。艾拉戈克钠是艾伯维与合作伙伴Neurocrine Bioscienc Chemicabookes共同研发的一种口服GnRH拮抗剂，2018年7月被FDA批准用于治疗与子宫内膜异位症相关的中度至重度疼痛，是十年来首个获FDA批准用于该适应症的口服疗法。据公开资料，艾拉戈克钠化合物专利2024年07月到期。目前，国内正大天晴、福安药业、齐鲁制药等企业在进行艾拉戈克钠人体生物等效性试验。总结作为一种常见妇科病，子宫内膜异位症摧残着不计其数的女性。目前，子宫内膜异位症治疗手段有限，治疗主要目的是缓解痛经。相对国外，我国子宫内膜异位症新药进展较慢，还未有任何一款GnRH拮抗剂被批准用于治疗子宫内膜异位症相关的疼痛，多款药物处于临床试验阶段，其中葆正医药引进的Linzagolix进展较快，已进入3期临床。值得一提是，在研子宫内膜异位症新药除了GnRH拮抗剂，还包括P2X3拮抗剂、PRLR靶向单抗。期待在药企的不懈努力下，我国子宫内膜异位症患者早日迎来新型治疗药物。 END 来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

突破性疗法临床1期临床2期申请上市ASH会议

2024-10-01

·drugs

Weight-Adjusted Waist Index Positively Tied to Overactive Bladder

TUESDAY, Oct. 1, 2024 -- The weight-adjusted waist index (WWI) may be able to predict future incidence of overactive bladder (OAB) in adults, according to a study published online Sept. 3 in Frontiers in Nutrition . Zeng Hui, from the Third Xiangya Hospital at Central South University in Changsha, China, and colleagues used data from the National Health and Nutrition Examination Survey (2009 to 2018; 35,950 individuals) to examine the correlation between WWI and OAB. The researchers found that individuals with a higher WWI had a higher risk for OAB (odds ratio, 1.41). The relationship between WWI and OAB was consistent across various population characteristics. There was a positive nonlinear relationship between WWI and OAB in smoothing curve fitting. The association between WWI and OAB was stronger than with other obesity-related indicators. "In this study, we found a positive relationship between higher WWI levels and an increased risk of OAB," the authors write. "Furthermore, the relationship between WWI and OAB is stronger than the correlation between other obesity markers and OAB, indicating that WWI may serve as a simple anthropometric indicator for predicting OAB." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果